US stock · Healthcare sector · Medical Devices
Company Logo

Boston Scientific Corporation

BSXNYSE

41.20

USD
+1.06
(+2.64%)
After Hours Market
75.74P/E
20Forward P/E
2.92P/E to S&P500
58.898BMarket CAP
- -Div Yield

Boston Scientific Corporation

NYSE:BSX

RECENT
PRICE

41.20

P/E
RATIO

75.74

(PEG:0.06)

P/E RATIO
RELATIVE
TO S&P

2.92

DIV
YLD

0.09%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

0.81 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 05/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

6.14

(2.81)

1.18

- -

5.62

(0.33)

0.38

- -

5.37

(1.36)

0.57

- -

5.43

(0.68)

0.31

- -

5.14

(0.70)

0.03

- -

5.05

0.29

0.47

- -

5.15

(2.89)

0.74

- -

5.33

(0.09)

0.62

- -

5.57

(0.09)

0.76

- -

5.57

(0.18)

0.26

- -

6.18

0.26

0.44

- -

6.60

0.08

0.81

- -

7.11

1.21

(0.00)

- -

7.71

3.38

0.99

- -

7.00

(0.06)

0.80

0.02

8.39

0.73

0.93

0.04

8.54

0.53

0.92

0.04

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.27

12.02

0.24

10.15

0.24

8.79

0.24

8.16

0.18

7.44

0.20

7.52

0.16

4.88

0.18

4.88

0.20

4.88

0.18

4.71

0.28

4.96

0.23

5.12

0.23

6.32

0.33

9.97

0.27

10.82

0.39

11.73

0.39

11.36

CAPEX per share

Book Value per share

1,273

1,487

1,499

1,508

1,518

1,509

1,407

1,341

1,324

1,341

1,358

1,370

1,381

1,392

1,417

1,417

1,425

Comm.Shares outs.(m)

(6.8)

(0.4)

- -

(44.5)

(2.6)

- -

(8.5)

(0.4)

- -

(13.5)

(0.2)

- -

(9.6)

(0.5)

- -

22.8

1.4

- -

(2.0)

(0.1)

- -

(106.1)

(6.2)

- -

(142.8)

(7.9)

- -

(95.8)

(4.8)

- -

82.9

3.7

- -

346.9

14.7

- -

26.5

1.1

- -

11.9

0.5

- -

(642.7)

(17.0)

0.1%

56.3

1.9

0.1%

75.7

2.9

0.1%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/12/21 | Q4)

Total liabilities
$15,607 m.

Total assets
$32,229 m.

Long-term debt
$9,190 m.

Cash and equiv.
$1,925 m.

Goodwill $11,988 m.

Retained earnings $(1,392) m.

Common stock 1,428 m. shares

Market Capitalisation
$57,383 m. (as of 27/5/22)

7,622

11.9%

7,249

(53.4)%

7,143

1.7%

7,380

(4.1)%

7,477

(4.4)%

8,386

5.3%

9,048

14.2%

9,823

15.3%

10,735

14.1%

9,913

(0.8)%

11,888

10.1%

12,162

10.8%

Revenue (m)

Operating margin

717

441

683

(4,068)

689

(121)

725

(119)

769

(239)

815

347

844

104

894

1,671

1,011

4,700

1,123

(82)

1,093

1,041

1,023

810

Depreciation (m)

Net profit (m)

31.3%

5.8%

0.9%

(56.1)%

45.7%

(1.7)%

76.6%

(1.6)%

63.2%

(3.2)%

(96.0)%

4.1%

88.7%

1.1%

(17.5)%

17.0%

(584.1)%

43.8%

(2.5)%

(0.8)%

3.3%

8.8%

9.8%

6.8%

Income tax rate

Net profit margin

1,298

4,257

11,353

1,250

4,252

6,870

1,187

4,237

6,539

760

3,859

6,457

1,041

5,674

6,320

(348)

5,420

6,733

(1,832)

3,776

7,011

(1,257)

4,771

8,725

(167)

8,579

13,877

3,013

9,118

15,327

2,043

9,190

16,623

2,043

9,190

16,623

Working capital (m)

Long-term debt (m)

Equity (m)

3.3%

4.3%

3.9%

(24.8)%

(22.4)%

(59.2)%

0.4%

0.6%

(1.9)%

(0.5)%

(1.7)%

(1.8)%

(0.9)%

(2.0)%

(3.8)%

5.5%

2.3%

5.2%

1.0%

6.1%

1.5%

12.4%

7.9%

19.2%

30.9%

3.8%

33.9%

1.1%

0.9%

(0.5)%

4.9%

4.4%

6.3%

4.7%

4.5%

4.9%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

217

1,734

1,925

Receivables

1,933

1,531

1,778

Inventory

1,579

1,351

1,610

Other

970

2,078

1,004

Current assets

4,699

6,694

6,317

Acc. Payable

542

513

794

Debt due

1,416

13

261

Other

2,908

3,155

3,219

Current liab.

4,866

3,681

4,274

100.0%

66.9%

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

(18.6)%

100.0%

(7.7)%

100.0%

1,683.3%

100.0%

(8.9)%

134.1%

- -

94.7%

4.2%

94.7%

4.2%

Plowback ratio

Div.&Repurch. to FCF

Boston Scientific Corporation (US) started trading on May 2, 1992 (cik: 0000885725), operates in the Healthcare sector (Medical Devices industry), has 41,000 full-time employees, and is led by Mr. Michael Mahoney. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

7.53%

5.93%

Cash flow

-5779.66%

-2558.61%

Earnings

54.19%

-10.70%

Dividends

- -

- -

Book value

25.60%

11.65%

Insider trading

Type

Shares

Date

Carruthers Wendy

Sale

7,500

05/16/22

Dockendorff Charles J

Award

4,877

05/05/22

Connors Nelda J

Award

4,877

05/05/22

Fujimori Yoshiaki

Award

4,877

05/05/22

James Donna

Award

4,877

05/05/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

2,543

2,003

2,659

2,709

9,914

2021

2,752

3,077

2,932

3,127

11,888

2022

3,026

- -

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

0.01

(0.10)

(0.11)

0.15

-0.06

2021

0.24

0.13

0.30

0.07

0.73

2022

0.08

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2019

- -

- -

- -

- -

- -

2020

- -

- -

- -

0.01

0.01

2021

0.01

0.01

0.01

0.01

0.04